Staphylococcus Aureus Bacteremia Clinical Trial
— SAB7Official title:
Efficacy of Seven and Fourteen Days of Antibiotic Treatment in Uncomplicated Staphylococcus Aureus Bacteremia: A Randomized, Non-blinded, Non-inferiority Interventional Study
Introduction: Staphylococcus aureus bacteremia (SAB) plays an important role in long-course antibiotic therapy. Current international guidelines recommend fourteen days of intravenous antibiotic treatment for SAB in order to minimize risks of secondary deep infections and complications. However, patients with simple SAB are known to have a low risk of complications. Reducing treatment length in uncomplicated SAB would reduce the total consumption of antibiotics, adverse events and duration of hospital admission. SAB7 seeks to determine if seven days of antibiotic treatment in patients with uncomplicated SAB is non-inferior to fourteen days of treatment. Method: The study is designed as a randomized, non-blinded, non-inferiority interventional study. Primary measure of outcome will be failure to treatment or recurrence of SAB twelve weeks after termination of antibiotic treatment. As a measure of secondary outcome the prevalence of severe adverse effects will be evaluated, in particular secondary infection with Clostridium difficile, mortality as well as public health related costs. Patients identified with uncomplicated SAB, are randomized 1:1 in two parallel arms to seven or fourteen days of antimicrobial treatment, respectively. Endpoints will be tested with a statistical non-inferiority margin of 10%. Conclusion: SAB 7 will determine if seven days of antibiotic treatment in patients with uncomplicated SAB is sufficient and safe, potentially modifying current treatment recommendations.
Status | Recruiting |
Enrollment | 284 |
Est. completion date | November 1, 2021 |
Est. primary completion date | May 1, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age > 18 years - Blood culture positive for Staphylococcus aureus - Antibiotic treatment with antimicrobial activity to S. aureus administrated within 12 hours of the first positive blood culture - Temperature < 37,5 degrees celsius at randomization - S. aureus negative follow-up blood culture obtained 48-96 hours after microbiological verified SAB. - Patients written consent obtained Exclusion Criteria: - Persistence of S. aureus bacteremia before randomization (S. aureus positive follow-up blood culture obtained 48-96 hours of the first positive blood culture) - Polymicrobial infection - Antibiotic treatment whit no antimicrobial activity to S. aureus administrated more than 12 hours of the first positive blood culture - Endocarditis or other intracardiac infection demonstrated with transthoracic or transesophageal echocardiography - Previous history of endocarditis - Pacemaker or other intracardiac implant - Failure to remove a likely focus of infection, such as central venous catheter within 72 hours of the first positive blood culture. - Prosthetics in joints and bones or vascular grafts - Pneumonia or infection involving bone or joints - Previously bone/join infection - S. aureus infection within the last 90 days - Pregnancy or breastfeeding - Neutropenia (blood neutrophils < 1,0 x 109/l) - Untreated cancer - Chemotherapy within 90 days. |
Country | Name | City | State |
---|---|---|---|
Denmark | Hvidovre Hospital | Hvidovre | Copenhagen |
Lead Sponsor | Collaborator |
---|---|
Thomas Benfield |
Denmark,
Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Jun 11;372(24):2368-9. doi: 10.1056/NEJMc1505190. — View Citation
Benfield T, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV, Skov R, Westh H, Skinhøj P. Increasing incidence but decreasing in-hospital mortality of adult Staphylococcus aureus bacteraemia between 1981 and 2000. Clin Microbiol Infect. 2007 Mar;13(3):257-63. — View Citation
Blyth CC, Darragh H, Whelan A, O'Shea JP, Beaman MH, McCarthy JS. Evaluation of clinical guidelines for the management of Staphylococcus aureus bacteraemia. Intern Med J. 2002 May-Jun;32(5-6):224-32. — View Citation
Ehni WF, Reller LB. Short-course therapy for catheter-associated Staphylococcus aureus bacteremia. Arch Intern Med. 1989 Mar;149(3):533-6. — View Citation
Fowler VG Jr, Sanders LL, Sexton DJ, Kong L, Marr KA, Gopal AK, Gottlieb G, McClelland RS, Corey GR. Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. Clin Infect Dis. 1998 Sep;27(3):478-86. — View Citation
Iannini PB, Crossley K. Therapy of Staphylococcus aureus bacteremia associated with a removable focus of infection. Ann Intern Med. 1976 May;84(5):558-60. — View Citation
Jensen AG, Wachmann CH, Espersen F, Scheibel J, Skinhøj P, Frimodt-Møller N. Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases. Arch Intern Med. 2002 Jan 14;162(1):25-32. — View Citation
Kaasch AJ, Fätkenheuer G, Prinz-Langenohl R, Paulus U, Hellmich M, Weiß V, Jung N, Rieg S, Kern WV, Seifert H; SABATO trial group (with linked authorship to the individuals in the Acknowledgements section). Early oral switch therapy in low-risk Staphylococcus aureus bloodstream infection (SABATO): study protocol for a randomized controlled trial. Trials. 2015 Oct 9;16:450. doi: 10.1186/s13063-015-0973-x. — View Citation
Larsen AR, Stegger M, Sørum M. spa typing directly from a mecA, spa and pvl multiplex PCR assay-a cost-effective improvement for methicillin-resistant Staphylococcus aureus surveillance. Clin Microbiol Infect. 2008 Jun;14(6):611-4. doi: 10.1111/j.1469-0691.2008.01995.x. Epub 2008 Apr 3. — View Citation
Mejer N, Westh H, Schønheyder HC, Jensen AG, Larsen AR, Skov R, Benfield T; Danish Staphylococcal Bacteraemia Study Group. Stable incidence and continued improvement in short term mortality of Staphylococcus aureus bacteraemia between 1995 and 2008. BMC Infect Dis. 2012 Oct 17;12:260. doi: 10.1186/1471-2334-12-260. — View Citation
Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis. 1987 Sep-Oct;9(5):891-907. Review. — View Citation
Mylotte JM, McDermott C. Staphylococcus aureus bacteremia caused by infected intravenous catheters. Am J Infect Control. 1987 Feb;15(1):1-6. — View Citation
Raad II, Sabbagh MF. Optimal duration of therapy for catheter-related Staphylococcus aureus bacteremia: a study of 55 cases and review. Clin Infect Dis. 1992 Jan;14(1):75-82. — View Citation
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ; UK Clinical Infection Research Group. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. 2011 Mar;11(3):208-22. doi: 10.1016/S1473-3099(10)70285-1. Review. — View Citation
Zeylemaker MM, Jaspers CA, van Kraaij MG, Visser MR, Hoepelman IM. Long-term infectious complications and their relation to treatment duration in catheter-related Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis. 2001 Jun;20(6):380-4. — View Citation
* Note: There are 15 references in all — Click here to view all references
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 90-day survival without clinical or microbiological failure to treatment or relapse | up to 90 days | ||
Secondary | Microbiologically failure to treatment | Verified S. aureus infection of the same genotype as the initial infection | less than 7 days after treatment termination | |
Secondary | Microbiologically relapse | Verified S. aureus infection of the same genotype as the initial infection | more than 7 days after treatment termination | |
Secondary | Clinical failure to treatment or relapse | Initiation of anti-staphylococcal therapy for more than 48 hours due to suspected recurrence. | Up to day 90 | |
Secondary | Mortality | All-cause mortality | Days 14, 28, 90 and 180 | |
Secondary | Severe adverse events | grade 3 or above adverse events | Up to 26 weeks | |
Secondary | Acute renal injury | A 1.5 fold increase in creatinine or a 25% decrease of the glomerular filtration rate (GFR) | Up to 26 weeks | |
Secondary | Clostridium difficile infection | Microbiologically verified C. difficile infection | Up to 26 weeks | |
Secondary | Multidrug-resistance organism | Microbiologically verified multidrug-resistance organism | Up to 26 weeks | |
Secondary | Health-associated costs | Public health related cost estimated from a general consideration of the expenses associated with hospitalization for SAB. | Up to 26 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05862025 -
Evaluation of the Usefulness of Echocardiography in Patients With Staphylococcus Aureus Bacteremia (ET-AUREUS Study).
|
N/A | |
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Recruiting |
NCT00622882 -
Early Infectious Disease Consultations in Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT06168474 -
Evaluating Simplified Layered Consent for Clinical Trials
|
N/A | |
Completed |
NCT03163446 -
Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia
|
Phase 2 | |
Not yet recruiting |
NCT06336824 -
Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia
|
Phase 3 | |
Completed |
NCT02357966 -
A Study of the Safety and Efficacy of 514G3 in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
|
Phase 1/Phase 2 | |
Recruiting |
NCT04886284 -
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
|
Phase 2 | |
Terminated |
NCT03089697 -
Phase IIa Clinical Study of N-Rephasin® SAL200
|
Phase 2 | |
Withdrawn |
NCT03761953 -
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
|
Phase 4 | |
Recruiting |
NCT06249451 -
Staphylococcus Aureus Bacteraemia (SAB)-Support-Study
|
N/A | |
Recruiting |
NCT02098850 -
Staphylococcus Aureus Bacteraemia in Adults
|
N/A | |
Completed |
NCT01701219 -
Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia
|
Phase 4 | |
Recruiting |
NCT05137119 -
Staphylococcus Aureus Network Adaptive Platform Trial
|
Phase 4 | |
Completed |
NCT03908086 -
Bloodstream Infections in Patients With Rheumatoid Arthritis
|
||
Terminated |
NCT04160468 -
Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase
|
Phase 3 | |
Completed |
NCT03138733 -
Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia
|
Phase 3 | |
Completed |
NCT02476487 -
The Benefit of FDG PET CT in the Treatment Algorithm of Staphylococcus Aureus Bacteremia
|
N/A | |
Recruiting |
NCT05184764 -
Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia
|
Phase 1/Phase 2 | |
Completed |
NCT01971762 -
Staphylococcus Aureus Bacteremia: Impact of an Intervention Program in Improving the Clinical Management and Review of the Clinical and Molecular Epidemiology
|
N/A |